Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors.
暂无分享,去创建一个
J A Parker | S. Goldhaber | J. Parker | D S Kanter | K M Mikkola | S R Patel | S Z Goldhaber | S. Patel | D. Kanter | K. Mikkola | J. Parker | S. Patel | Katriina M. Mikkola
[1] P. Mombaerts,et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. , 1988, Circulation.
[2] S. Goldhaber,et al. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. , 1994, Chest.
[3] B. Hyman,et al. Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy , 1995 .
[4] F. Schiele,et al. Safety of thrombolytic therapy in elderly patients with massive pulmonary embolism: a comparison with nonelderly patients. , 1993, Journal of the American College of Cardiology.
[5] J. Garcìa,et al. Pathology of hypertensive arteriopathy. , 1992, Neurosurgery clinics of North America.
[6] E. Braunwald,et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion , 1993, The Lancet.
[7] Benraad Ah,et al. POTASSIUM CHLORIDE AND INTESTINAL ULCERATION. , 1965 .
[8] R. Califf,et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. , 1995, Circulation.
[9] J. Toole,et al. Clinical and computerized tomographic study of hypertensive intracerebral hemorrhage. , 1978, Archives of neurology.
[10] C M O'Connor,et al. CT patterns of intracranial hemorrhage complicating thrombolytic therapy for acute myocardial infarction. , 1991, Radiology.
[11] G. Meyer,et al. Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism. , 1992, The American journal of cardiology.
[12] J. Gore,et al. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction , 1995, Neurology.
[13] R. Califf,et al. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. , 1989, Chest.
[14] J. Hirsh,et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. , 1990, Chest.
[15] S. Goldhaber,et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. , 1992, Journal of the American College of Cardiology.
[16] R. Tracy,et al. Intracerebral hemorrhage related to cerebral amyloid angiopathy and T‐PA treatment , 1991, Annals of neurology.
[17] J. Loscalzo,et al. Perspectives on Treatment of Acute Pulmonary Embolism with Tissue Plasminogen Activator , 1987, Seminars in thrombosis and hemostasis.
[18] Daniel B Hier,et al. Anticoagulant‐related intracerebral hemorrhage , 1985, Neurology.
[19] E. Braunwald,et al. RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM , 1988, The Lancet.
[20] G. Simonneau,et al. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. , 1994, Chest.
[21] E. Lesaffre,et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. , 1992, Journal of the American College of Cardiology.
[22] J. Loscalzo,et al. Thrombolytic therapy of acute pulmonary embolism: current status and future potential. , 1987, Journal of the American College of Cardiology.
[23] E. Freis. Hypertension. A challenge in preventive cardiology. , 1973, Circulation.
[24] E. Braunwald,et al. ACUTE PULMONARY EMBOLISM TREATED WITH TISSUE PLASMINOGEN ACTIVATOR , 1986, The Lancet.